Nicotinic acetylcholine receptors
More information on this family may be found on the IUPHAR-DB family and introduction pages.
Nicotinic acetylcholine receptors are members of the Cys-loop family of transmitter-gated ion channels that includes the GABAA, strychnine-sensitive glycine and 5-HT3 receptors [2,30,36-37,42]. All nicotinic receptors are pentamers in which each of the five subunits contains four α-helical transmembrane domains. Genes (Ensembl family ID ENSF00000000049) encoding a total of 17 subunits (α1-10, β1-4, γ, δ and ε) have been identified [25]. All subunits with the exception of α8 (present in avian species) have been identified in mammals. All α subunits possess two tandem cysteine residues near to the site involved in acetylcholine binding, and subunits not named α lack these residues [30]. The orthosteric ligand binding site is formed by residues within at least three peptide domains on the α subunit (principal component), and three on the adjacent subunit (complementary component). nAChRs contain several allosteric modulatory sites. One such site, for positive allosteric modulators (PAMs) and allosteric agonists, has been proposed to reside within an intrasubunit cavity between the four transmembrane domains [16,44]; see also [21]). The high resolution crystal structure of the molluscan acetylcholine binding protein, a structural homologue of the extracellular binding domain of a nicotinic receptor pentamer, in complex with several nicotinic receptor ligands (e.g.[9]) and the crystal structure of the extracellular domain of the α1 subunit bound to α-bungarotoxin at 1.94 Å resolution [14], has revealed the orthosteric binding site in detail (reviewed in [10,25,35-36]). Nicotinic receptors at the somatic neuromuscular junction of adult animals have the stoichiometry (α1)2β1δε, whereas an extrajunctional (α1)2β1γδ receptor predominates in embryonic and denervated skeletal muscle and other pathological states. Other nicotinic receptors are assembled as combinations of α(2-6) and &beta(2-4) subunits. For α2, α3, α4 and β2 and β4 subunits, pairwise combinations of α and β (e.g. α3β4 and α4β2) are sufficient to form a functional receptor in vitro, but far more complex isoforms may exist in vivo (reviewed in [18-19,30]). There is strong evidence that the pairwise assembly of some α and β subunits can occur with variable stoichiometry [e.g. (α4)2(β2)2 or (α4)3(β2)2] which influences the biophysical and pharmacological properties of the receptor [30]. α5 and β3 subunits lack function when expressed alone, or pairwise, but participate in the formation of functional hetero-oligomeric receptors when expressed as a third subunit with another α and β pair [e.g. α4α5αβ2, α4αβ2β3, α5α6β2, see [30] for further examples]. The α6 subunit can form a functional receptor when co-expressed with β4 in vitro, but more efficient expression ensues from incorporation of a third partner, such as β3 [43]. The α7, α8, and α9 subunits form functional homo-oligomers, but can also combine with a second subunit to constitute a hetero-oligomeric assembly (e.g. α7β2 and α9α10). For functional expression of the α10 subunit, co-assembly with α9 is necessary. The latter, along with the α10 subunit, appears to be largely confined to cochlear and vestibular hair cells. Comprehensive listings of nicotinic receptor subunit combinations identified from recombinant expression systems, or in vivo, are given in [30]. In addition, numerous proteins interact with nicotinic ACh receptors modifying their assembly, trafficking to and from the cell surface, and activation by ACh (reviewed by [4,24,29]).
The nicotinic receptor subcommittee of NC-IUPHAR has recommended a nomenclature and classification scheme for nicotinic acetylcholine (nACh) receptors based on the subunit composition of known, naturally- and/or heterologously-expressed nACh receptor subtypes [27]. Headings for this table reflect abbreviations designating nACh receptor subtypes based on the predominant α subunit contained in that receptor subtype. An asterisk following the indicated α subunit denotes that other subunits are known to, or may, assemble with the indicated α subunit to form the designated nACh receptor subtype(s). Where subunit stoichiometries within a specific nACh receptor subtype are known, numbers of a particular subunit larger than 1 are indicated by a subscript following the subunit (enclosed in parentheses – see also [13]).
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
Albuquerque, EX; Pereira, EF; Alkondon, M; Rogers, SW. (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev., 89 (1): 73-120. [PMID:19126755]
Araud, T; Wonnacott, S; Bertrand, D. (2010) Associated proteins: The universal toolbox controlling ligand gated ion channel function. Biochem. Pharmacol., 80 (2): 160-9. [PMID:20346921]
Arias, HR. (2010) Positive and negative modulation of nicotinic receptors. Adv Protein Chem Struct Biol, 80: 153-203. [PMID:21109220]
Arneric, SP; Holladay, M; Williams, M. (2007) Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem. Pharmacol., 74 (8): 1092-101. [PMID:17662959]
Balfour, DJ. (2009) The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol, (192): 209-33. [PMID:19184651]
Benowitz, NL. (2009) Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol., 49: 57-71. [PMID:18834313]
Champtiaux, N; Changeux, JP. (2004) Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. Prog. Brain Res., 145: 235-51. [PMID:14650919]
Changeux, JP; Taly, A. (2008) Nicotinic receptors, allosteric proteins and medicine. Trends Mol Med, 14 (3): 93-102. [PMID:18262468]
Collingridge, GL; Olsen, RW; Peters, J; Spedding, M. (2009) A nomenclature for ligand-gated ion channels. Neuropharmacology, 56 (1): 2-5. [PMID:18655795]
D'hoedt, D; Bertrand, D. (2009) Nicotinic acetylcholine receptors: an overview on drug discovery. Expert Opin. Ther. Targets, 13 (4): 395-411. [PMID:19335063]
Dajas-Bailador, F; Wonnacott, S. (2004) Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol. Sci., 25 (6): 317-24. [PMID:15165747]
Faghih, R; Gopalakrishnan, M; Briggs, CA. (2008) Allosteric modulators of the alpha7 nicotinic acetylcholine receptor. J. Med. Chem., 51 (4): 701-12. [PMID:18198823]
Fucile, S. (2004) Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium, 35 (1): 1-8. [PMID:14670366]
Gotti, C; Clementi, F; Fornari, A; Gaimarri, A; Guiducci, S; Manfredi, I; Moretti, M; Pedrazzi, P; Pucci, L; Zoli, M. (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol., 78 (7): 703-11. [PMID:19481063]
Gotti, C; Zoli, M; Clementi, F. (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci., 27 (9): 482-91. [PMID:16876883]
Hogg, RC; Bertrand, D. (2004) Nicotinic acetylcholine receptors as drug targets. Curr Drug Targets CNS Neurol Disord, 3 (2): 123-30. [PMID:15078187]
Hogg, RC; Raggenbass, M; Bertrand, D. (2003) Nicotinic acetylcholine receptors: from structure to brain function. Rev. Physiol. Biochem. Pharmacol., 147: 1-46. [PMID:12783266]
Jensen, AA; Frølund, B; Liljefors, T; Krogsgaard-Larsen, P. (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J. Med. Chem., 48 (15): 4705-45. [PMID:16033252]
Jones, AK; Buckingham, SD; Sattelle, DB. (2010) Proteins interacting with nicotinic acetylcholine receptors: expanding functional and therapeutic horizons. Trends Pharmacol. Sci., 31 (10): 455-62. [PMID:20674046]
Kalamida, D; Poulas, K; Avramopoulou, V; Fostieri, E; Lagoumintzis, G; Lazaridis, K; Sideri, A; Zouridakis, M; Tzartos, SJ. (2007) Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J., 274 (15): 3799-845. [PMID:17651090]
Letchworth, SR; Whiteaker, P. (2011) Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors. Biochem. Pharmacol., 82 (8): 862-72. [PMID:21736871]
Lukas, RJ; Changeux, JP; Le Novère, N; Albuquerque, EX; Balfour, DJ; Berg, DK; Bertrand, D; Chiappinelli, VA; Clarke, PB; Collins, AC; et al.. (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev., 51 (2): 397-401. [PMID:10353988]
Millar, NS. (2008) RIC-3: a nicotinic acetylcholine receptor chaperone. Br. J. Pharmacol., 153 Suppl 1: S177-83. [PMID:18246096]
Millar, NS; Gotti, C. (2009) Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology, 56 (1): 237-46. [PMID:18723036]
Millar, NS; Harkness, PC. (2008) Assembly and trafficking of nicotinic acetylcholine receptors (Review). Mol. Membr. Biol., 25 (4): 279-92. [PMID:18446614]
Miwa, JM; Freedman, R; Lester, HA. (2011) Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron, 70 (1): 20-33. [PMID:21482353]
Olivera, BM; Quik, M; Vincler, M; McIntosh, JM. (2008) Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applications. Channels (Austin), 2 (2): 143-52. [PMID:18849660]
Pandya, A; Yakel, JL. (2011) Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors. Biochem. Pharmacol., 82 (8): 952-8. [PMID:21596025]
Romanelli, MN; Gratteri, P; Guandalini, L; Martini, E; Bonaccini, C; Gualtieri, F. (2007) Central nicotinic receptors: structure, function, ligands, and therapeutic potential. ChemMedChem, 2 (6): 746-67. [PMID:17295372]
Rucktooa, P; Smit, AB; Sixma, TK. (2009) Insight in nAChR subtype selectivity from AChBP crystal structures. Biochem. Pharmacol., 78 (7): 777-87. [PMID:19576182]
Sharma, G; Vijayaraghavan, S. (2008) Nicotinic receptors containing the alpha7 subunit: a model for rational drug design. Curr. Med. Chem., 15 (28): 2921-32. [PMID:19075644]
Sine, SM; Engel, AG. (2006) Recent advances in Cys-loop receptor structure and function. Nature, 440 (7083): 448-55. [PMID:16554804]
Steinlein, OK; Bertrand, D. (2008) Neuronal nicotinic acetylcholine receptors: from the genetic analysis to neurological diseases. Biochem. Pharmacol., 76 (10): 1175-83. [PMID:18691557]
Taly, A; Corringer, PJ; Guedin, D; Lestage, P; Changeux, JP. (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov, 8 (9): 733-50. [PMID:19721446]
Tsetlin, V; Hucho, F. (2009) Nicotinic acetylcholine receptors at atomic resolution. Curr Opin Pharmacol, 9 (3): 306-10. [PMID:19428299]
Tsetlin, V; Kuzmin, D; Kasheverov, I. (2011) Assembly of nicotinic and other Cys-loop receptors. J. Neurochem., 116 (5): 734-41. [PMID:21214570]
Tsetlin, V; Utkin, Y; Kasheverov, I. (2009) Polypeptide and peptide toxins, magnifying lenses for binding sites in nicotinic acetylcholine receptors. Biochem. Pharmacol., 78 (7): 720-31. [PMID:19501053]
Unwin, N. (2005) Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J. Mol. Biol., 346 (4): 967-89. [PMID:15701510]
Wu, J; Lukas, RJ. (2011) Naturally-expressed nicotinic acetylcholine receptor subtypes. Biochem. Pharmacol., 82 (8): 800-7. [PMID:21787755]
Yang, KC; Jin, GZ; Wu, J. (2009) Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology. Acta Pharmacol. Sin., 30 (6): 740-51. [PMID:19498417]
Zouridakis, M; Zisimopoulou, P; Poulas, K; Tzartos, SJ. (2009) Recent advances in understanding the structure of nicotinic acetylcholine receptors. IUBMB Life, 61 (4): 407-23. [PMID:19319967]
1. Acker, BA; Jacobsen, EJ; Rogers, BN; Wishka, DG; Reitz, SC; Piotrowski, DW; Myers, JK; Wolfe, ML; Groppi, VE; Thornburgh, BA; et al.. (2008) Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg. Med. Chem. Lett., 18 (12): 3611-5. [PMID:18490160]
2. Albuquerque, EX; Pereira, EF; Alkondon, M; Rogers, SW. (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev., 89 (1): 73-120. [PMID:19126755]
3. Anderson, DJ; Bunnelle, W; Surber, B; Du, J; Surowy, C; Tribollet, E; Marguerat, A; Bertrand, D; Gopalakrishnan, M. (2008) [3H]A-585539 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a novel high-affinity alpha7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain. J. Pharmacol. Exp. Ther., 324 (1): 179-87. [PMID:17959745]
4. Araud, T; Wonnacott, S; Bertrand, D. (2010) Associated proteins: The universal toolbox controlling ligand gated ion channel function. Biochem. Pharmacol., 80 (2): 160-9. [PMID:20346921]
5. Bitner, RS; Bunnelle, WH; Anderson, DJ; Briggs, CA; Buccafusco, J; Curzon, P; Decker, MW; Frost, JM; Gronlien, JH; Gubbins, E; et al.. (2007) Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci., 27 (39): 10578-87. [PMID:17898229]
6. Bodnar, AL; Cortes-Burgos, LA; Cook, KK; Dinh, DM; Groppi, VE; Hajos, M; Higdon, NR; Hoffmann, WE; Hurst, RS; Myers, JK; et al.. (2005) Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J. Med. Chem., 48 (4): 905-8. [PMID:15715459]
7. Broad, LM; Zwart, R; Pearson, KH; Lee, M; Wallace, L; McPhie, GI; Emkey, R; Hollinshead, SP; Dell, CP; Baker, SR; et al.. (2006) Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J. Pharmacol. Exp. Ther., 318 (3): 1108-17. [PMID:16738207]
8. Buisson, B; Gopalakrishnan, M; Arneric, SP; Sullivan, JP; Bertrand, D. (1996) Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: A patch-clamp study. J. Neurosci., 16 (24): 7880-91. [PMID:8987816]
9. Celie, PH; van Rossum-Fikkert, SE; van Dijk, WJ; Brejc, K; Smit, AB; Sixma, TK. (2004) Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron, 41 (6): 907-14. [PMID:15046723]
10. Changeux, JP; Taly, A. (2008) Nicotinic receptors, allosteric proteins and medicine. Trends Mol Med, 14 (3): 93-102. [PMID:18262468]
11. Chavez-Noriega, LE; Crona, JH; Washburn, MS; Urrutia, A; Elliott, KJ; Johnson, EC. (1997) Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther., 280 (1): 346-56. [PMID:8996215]
12. Chen, Y; Sharples, TJ; Phillips, KG; Benedetti, G; Broad, LM; Zwart, R; Sher, E. (2003) The nicotinic alpha 4 beta 2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices. Neuropharmacology, 45 (3): 334-44. [PMID:12871651]
13. Collingridge, GL; Olsen, RW; Peters, J; Spedding, M. (2009) A nomenclature for ligand-gated ion channels. Neuropharmacology, 56 (1): 2-5. [PMID:18655795]
14. Dellisanti, CD; Yao, Y; Stroud, JC; Wang, ZZ; Chen, L. (2007) Crystal structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 A resolution. Nat. Neurosci., 10 (8): 953-62. [PMID:17643119]
15. Dinklo, T; Shaban, H; Thuring, JW; Lavreysen, H; Stevens, KE; Zheng, L; Mackie, C; Grantham, C; Vandenberk, I; Meulders, G; et al.. (2011) Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor. J. Pharmacol. Exp. Ther., 336 (2): 560-74. [PMID:21084390]
16. Gill, JK; Savolainen, M; Young, GT; Zwart, R; Sher, E; Millar, NS. (2011) Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc. Natl. Acad. Sci. U.S.A., 108 (14): 5867-72. [PMID:21436053]
17. Gordon, JC; Phillips, E; Gurley, DA; Heys, JR; Lazor, LA; Barthlow, HG; Mallamaci, MA; Keith, RA. (2010) In vitro binding characteristics of [3H]AZ11637326, a novel alpha7-selective neuronal nicotinic receptor agonist radioligand. Eur. J. Pharmacol., 645 (1-3): 63-9. [PMID:20674564]
18. Gotti, C; Clementi, F; Fornari, A; Gaimarri, A; Guiducci, S; Manfredi, I; Moretti, M; Pedrazzi, P; Pucci, L; Zoli, M. (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol., 78 (7): 703-11. [PMID:19481063]
19. Gotti, C; Zoli, M; Clementi, F. (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci., 27 (9): 482-91. [PMID:16876883]
20. Hauser, TA; Kucinski, A; Jordan, KG; Gatto, GJ; Wersinger, SR; Hesse, RA; Stachowiak, EK; Stachowiak, MK; Papke, RL; Lippiello, PM; et al.. (2009) TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol., 78 (7): 803-12. [PMID:19482012]
21. Hibbs, RE; Gouaux, E. (2011) Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature, 474 (7349): 54-60. [PMID:21572436]
22. Hurst, RS; Hajós, M; Raggenbass, M; Wall, TM; Higdon, NR; Lawson, JA; Rutherford-Root, KL; Berkenpas, MB; Hoffmann, WE; Piotrowski, DW; et al.. (2005) A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci., 25 (17): 4396-405. [PMID:15858066]
23. Jensen, AA; Frølund, B; Liljefors, T; Krogsgaard-Larsen, P. (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J. Med. Chem., 48 (15): 4705-45. [PMID:16033252]
24. Jones, AK; Buckingham, SD; Sattelle, DB. (2010) Proteins interacting with nicotinic acetylcholine receptors: expanding functional and therapeutic horizons. Trends Pharmacol. Sci., 31 (10): 455-62. [PMID:20674046]
25. Kalamida, D; Poulas, K; Avramopoulou, V; Fostieri, E; Lagoumintzis, G; Lazaridis, K; Sideri, A; Zouridakis, M; Tzartos, SJ. (2007) Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J., 274 (15): 3799-845. [PMID:17651090]
26. Lee, CH; Zhu, C; Malysz, J; Campbell, T; Shaughnessy, T; Honore, P; Polakowski, J; Gopalakrishnan, M. (2011) α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain. Biochem. Pharmacol., 82 (8): 959-66. [PMID:21763685]
27. Lukas, RJ; Changeux, JP; Le Novère, N; Albuquerque, EX; Balfour, DJ; Berg, DK; Bertrand, D; Chiappinelli, VA; Clarke, PB; Collins, AC; et al.. (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev., 51 (2): 397-401. [PMID:10353988]
28. Malysz, J; Grønlien, JH; Anderson, DJ; Håkerud, M; Thorin-Hagene, K; Ween, H; Wetterstrand, C; Briggs, CA; Faghih, R; Bunnelle, WH; et al.. (2009) In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile. J. Pharmacol. Exp. Ther., 330 (1): 257-67. [PMID:19389923]
29. Millar, NS. (2008) RIC-3: a nicotinic acetylcholine receptor chaperone. Br. J. Pharmacol., 153 Suppl 1: S177-83. [PMID:18246096]
30. Millar, NS; Gotti, C. (2009) Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology, 56 (1): 237-46. [PMID:18723036]
31. Papke, RL; Dwoskin, LP; Crooks, PA; Zheng, G; Zhang, Z; McIntosh, JM; Stokes, C. (2008) Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras. Neuropharmacology, 54 (8): 1189-200. [PMID:18448138]
32. Papke, RL; Sanberg, PR; Shytle, RD. (2001) Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J. Pharmacol. Exp. Ther., 297 (2): 646-56. [PMID:11303054]
33. Papke, RL; Webster, JC; Lippiello, PM; Bencherif, M; Francis, MM. (2000) The activation and inhibition of human nicotinic acetylcholine receptor by RJR-2403 indicate a selectivity for the alpha4beta2 receptor subtype. J. Neurochem., 75 (1): 204-16. [PMID:10854263]
34. Paul, M; Kindler, CH; Fokt, RM; Dresser, MJ; Dipp, NC; Yost, CS. (2002) The potency of new muscle relaxants on recombinant muscle-type acetylcholine receptors. Anesth. Analg., 94 (3): 597-603; table of contents. [PMID:11867382]
35. Rucktooa, P; Smit, AB; Sixma, TK. (2009) Insight in nAChR subtype selectivity from AChBP crystal structures. Biochem. Pharmacol., 78 (7): 777-87. [PMID:19576182]
36. Sine, SM; Engel, AG. (2006) Recent advances in Cys-loop receptor structure and function. Nature, 440 (7083): 448-55. [PMID:16554804]
37. Taly, A; Corringer, PJ; Guedin, D; Lestage, P; Changeux, JP. (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov, 8 (9): 733-50. [PMID:19721446]
38. Timmermann, DB; Grønlien, JH; Kohlhaas, KL; Nielsen, EØ; Dam, E; Jørgensen, TD; Ahring, PK; Peters, D; Holst, D; Christensen, JK; et al.. (2007) An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J. Pharmacol. Exp. Ther., 323 (1): 294-307. [PMID:17625074]
39. Williams, DK; Wang, J; Papke, RL. (2011) Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem. Pharmacol., 82 (8): 915-30. [PMID:21575610]
40. Wishka, DG; Walker, DP; Yates, KM; Reitz, SC; Jia, S; Myers, JK; Olson, KL; Jacobsen, EJ; Wolfe, ML; Groppi, VE; et al.. (2006) Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. J. Med. Chem., 49 (14): 4425-36. [PMID:16821801]
41. Wu, J; Liu, Q; Yu, K; Hu, J; Kuo, YP; Segerberg, M; St John, PA; Lukas, RJ. (2006) Roles of nicotinic acetylcholine receptor beta subunits in function of human alpha4-containing nicotinic receptors. J. Physiol. (Lond.), 576 (Pt 1): 103-18. [PMID:16825297]
42. Wu, J; Lukas, RJ. (2011) Naturally-expressed nicotinic acetylcholine receptor subtypes. Biochem. Pharmacol., 82 (8): 800-7. [PMID:21787755]
43. Yang, KC; Jin, GZ; Wu, J. (2009) Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology. Acta Pharmacol. Sin., 30 (6): 740-51. [PMID:19498417]
44. Young, GT; Zwart, R; Walker, AS; Sher, E; Millar, NS. (2008) Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc. Natl. Acad. Sci. U.S.A., 105 (38): 14686-91. [PMID:18791069]
|
@GuidetoPHARM Like us on Facebook Privacy and Cookie Policy |


Commonly used agonists of nACh receptors that display limited discrimination in functional assays between receptor subtypes include A-85380, cytisine, DMPP, epibatidine, nicotine and the natural transmitter, acetylcholine (ACh). A summary of their profile across differing receptors is provided in [19] and quantitative data across numerous assay systems are summarized in [23]. Quantitative data presented in the table for commonly used antagonists and channel blockers for human receptors studied under voltage-clamp are from [8,11,31-32,34,41]. Type I PAMs increase peak agonist-evoked responses but have little, or no, effect on the rate of desensitization of α7 nicotinic ACh receptors whereas type II PAMs also cause a large reduction in desensitization (reviewed in [39]).